Sequencing Method that Maps Breast Cell Differentiation Provides Insight to Cancer Development
Salk Institute researchers have used of a state-of-the-art technology known as single-nucleus (sn) assay for transposase-accessible chromatin (ATAC) sequencing (snATAC-seq) to profile how specific...
Novartis Solicits Proposals to Advance Biomarker Testing in Cancer
Novartis is soliciting proposals from patient advocacy organizations for initiatives designed to expand and improve understanding of biomarker testing among people with cancer that...
Single-Cell Transcriptional Analysis Predicts Melanoma Drug Response
Investigators at the Moffitt Cancer Center’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence have just released findings from a new study...
Artificial Intelligence Enhances Oncology
The volume of information that needs to be analyzed to make precision medicine a reality in cancer care is often beyond the realm of the human mind. That’s where artificial intelligence steps in
Illumina and Qiagen Enter 15-Year Diagnostics Partnership
Two leaders in genomics and molecular analysis, Illumina and QIAGEN, have announced a 15-year partnership that the companies say is aimed at increasing the...
![Centogene’s CentoMD® rare disease variant database will be integrated into Qiagen’s bioinformatics suite in a rare disease bioinformatics collaboration by the companies. [Source: alengo/Getty]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1291-218x150.jpeg "NIH Commits $38M to Rare Disease Research and Affiliated Data Center")
NIH Commits $38M to Rare Disease Research and Affiliated Data Center
About $31 million in grants has been awarded by The National Institutes of Health in fiscal year 2019 to 20 teams in order to...
Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
Prometheus Biosciences said its bioinformatics platform and advanced machine learning techniques will be used by Takeda Pharmaceutical as part of a global collaboration to...
![Verge Genomics has raised $32 million in Series A financing toward further development of new treatments by combining machine learning and neuroscience with experimental biology. [Source: kentoh/Getty Images]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1787-218x150.jpeg "Novartis, with Assist from Microsoft, Launches AI Innovation Lab")
Novartis, with Assist from Microsoft, Launches AI Innovation Lab
Novartis will establish an “AI innovation lab” designed to enable its research and commercial employees to use Microsoft’s artificial intelligence solutions across operations, with...
Congenica to Integrate Genomenon’s Mastermind into its Clinical Decision Support Tool
Two new reference data sources, Mastermind and DECIPHER, are being added to Congenica’s clinical decision support platform for genomic data interpretation. Genomenon’s Mastermind, which...
![Berg will partner with Massachusetts General Hospital and Brigham and Women's Hospital to study potential biomarkers for Alzheimer's and other neurodegenerative disorders from Harvard Biomarker Study biospecimens. [Source: ajcity.net]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1397-218x150.jpeg "NIA Invests $73 Million in New Alzheimer’s Research Centers")
NIA Invests $73 Million in New Alzheimer’s Research Centers
The National Institute on Aging (NIA) has committed an estimated $73 million over the next five years to “diversify and reinvigorate the Alzheimer’s disease...
